Moderna Inc. diskutieren
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at UBS Group AG from $108.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Leerink Partners from $31.00 to $27.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $112.00 to $99.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Bank of America Co. from $41.00 to $34.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at UBS Group AG from $96.00 to $78.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $26.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Bank of America Corporation from $26.00 to $25.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Leerink Partners from $18.00 to $15.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $26.00 to $25.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Bank of America Corporation from $24.00 to $21.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its "underperform" rating reaffirmed by analysts at Wolfe Research. They now have a $17.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target raised by analysts at Leerink Partners from $15.00 to $18.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) was given a new $63.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to a "buy" rating.
Ratings data for MRNA provided by MarketBeat
Neueste Beiträge
Royal_Bank_of_Canada in ASML Holding N.V. ADR diskutieren